Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

ATLANTA, May 15, 2012 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced its financial results for the three months ended March 31, 2012 and provided a business update.

"We are delighted with recent developments that have strengthened and advanced our HIV/AIDS vaccine program," said Chairman of the Board David Dodd. "Our Phase 1/2 therapeutic vaccine trial continues to enroll patients and we expect full enrollment by the end of 2012. The HIV Vaccine Trials Network (HVTN) continues toward the goal of compiling the data for the Phase 2a trial of our preventive vaccine by the end of 2012 and recently opened a new Phase 1 trial of the next generation of our preventive vaccine, which utilizes granulocyte-macrophase colony-stimulating factor (GM-CSF) as an adjuvant to boost the immune response. We are gratified that the NIH-supported HVTN continues to recognize the potential life-saving value of our vaccine technology and has committed substantial resources toward advancing our clinical progress. Most important, we have a highly competent and dedicated team, focused on excellence in execution related to our ongoing development programs."

Robert T. McNally, PhD, GeoVax President and CEO, remarked, "We are particularly pleased with the outstanding preclinical results we recently reported for our next generation preventive vaccine, which co-expresses GM-CSF as an adjuvant in the DNA vaccine used to prime the immune system. Our studies demonstrated an unprecedented 90% reduction in per exposure risk of transmission for the E660 strain of SIV (simian HIV) and 72% reduction in per exposure risk of transmission for SIV251, the most potent strain of SIV used in non-human primate models. These are extremely rigorous models, with the primates receiving repeated weekly exposures to SIV of up to 300 times the amount one would expect to see in humans. Our data ind
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Ameritox SM , the nation,s leader in ... Drugs to Heroin," a research report that provides concrete ... examines deadly trends that have created a unique heroin ... The report is based on data ... It examines five trends that distinguish the heroin abuse ...
(Date:9/2/2014)... BARCELONA , Spanien, September 2, ... -- Das auf dem ESC-Kongress 2014 ... die Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten ...    Die Daten ... eingetragenen Patienten, einer innovativen und unabhängigen ...
(Date:9/2/2014)... Spain , September 2, 2014 ... decisions, including patients, quality of life and treatment satisfaction ... 2 ]   ... ESC Congress 2014, 02 September 2014, Barcelona, ... results of the PREvention oF thromboembolic events-European Registry in ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8
... (Nasdaq: IDIX ), a biopharmaceutical company engaged ... treatment of human viral diseases, today reported unaudited financial ... September 30, 2010. At September 30, 2010, Idenix,s cash ... Third Quarter 2010 Financial ResultsFor the third quarter ended ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today ... ViroPharma, will present at the Oppenheimer 21st Annual Healthcare ... 2010.  The conference is being held at the Waldorf=Astoria ... president and chief financial officer, of ViroPharma, will present ...
Cached Medicine Technology:Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 3Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 4Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 5ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences 2
(Date:9/2/2014)... reveals that unplanned births out-of-hospital in Norway are associated ... Acta Obstetricia et Gynecologica Scandinavica , a journal of ... indicate that young women who have given birth at ... areas are more likely to have unplanned deliveries, which ... , In 2013, close to 60,000 babies were born ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 Everyone of a ... offers two easy ways to help minimize them and improve ... ingredients. Aging skin needs to boost collagen levels, which diminish ... sagging skin. Skin also needs to be well hydrated, as ... from the sun and good diet that nourishes skin, two ...
(Date:9/2/2014)... Chicago, Illinois (PRWEB) September 02, 2014 ... Hospital Chief Executive Officer and Chief Information Officer ... Ritz Carlton Chicago. , Becker's Hospital Review Chief ... bring together hospital and health system Chief Executive ... other hospital and health system executives through ...
(Date:9/2/2014)... iFitDress.com, a famous online supplier of wedding dresses and ... 2014 seashell wedding dresses . Additionally, these elegant ... proportion of them are priced under $190. , All ... by the most skilled workers. Along with seashell wedding ... wedding gowns, white halter wedding gowns, regency evening outfits, ...
(Date:9/2/2014)... The exciting information sessions and AMTC auditions will ... and Bob Wiley. The team of scouts prayerfully ... desire to illuminate entertainment with the light of Christ. ... to join the Bridge Training Program and ... 6, Charlotte Convention Center, 501 South College St., Charlotte, ...
Breaking Medicine News(10 mins):Health News:Unplanned births out-of-hospital increases risk of infant mortality 2Health News:2 Natural Ways to Relax and Reduce Wrinkles From Sublime Beauty® 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 3Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 4Health News:Discounted Seashell Wedding Dresses Currently Provided By iFitDress.com 2Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2
... (Nasdaq: MEMY ) today announced the issuance ... matter patent,protection for a series of nicotinic alpha-7 ... which are both being developed,in partnership with Roche ... disease and cognitive impairment associated with schizophrenia,(CIAS). The ...
... Baby boomers are turning 62,every seven seconds. ... their,own health care in their senior years, says ... Care insurance lawyer., (Photo: http://www.newscom.com/cgi-bin/prnh/20070717/NYFNSC02 ), ... Care. It has been sold and,marketed to our ...
... ConvergeWireless Inc., of Ontario Canada, a Value Added Wireless Application ... been certified by the AT&T Developer Program. MyMileageGenie & MyFormsGenie ... for Enterprise Sales. , ... Ontario, ...
... DETROIT, Oct. 24 For the second ... has been chosen as the most,preferred hospital ... to the,2008 Cancer Treatment Preference Profile Survey ... http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO ), The annual survey, ...
... body, checking arteries lowers risk of further injury , , THURSDAY, ... is only the first step in saving a life after ... advisory, published in the Oct. 23 issue of Circulation ... resuscitation or risk the losing the patient to the original ...
... Alternext US: FIT), a leading provider of integrated,employee ... report financial results for the third quarter ended ... the market closes. The company will also,hold a ... results. Participating,in the call will be Dr. Gregg ...
Cached Medicine News:Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 3Health News:Expert Says Conseco Trust May Significantly Alter The Senior Health Care Market 2Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 2Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 3Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 4Health News:Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan 2Health News:Speedy Care After Heart Attack Key to Survival 2Health News:HealthFitness Corporation to Report 2008 Third Quarter Financial Results 2
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTT/1P chairs are recommended for ... clean room, static control, health care ...
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: